Optimas Appoints Industry Veteran Phil Battaglia as Chief Financial Officer
WOOD DALE, IL, Apr 18, 2023 – (ACN Newswire) – Optimas Solutions, a global industrial…
Year: 2023
The 21st Conference on International Exchange of Professionals Opens in Shenzhen
SHENZHEN, CHINA, Apr 18, 2023 – (ACN Newswire) – On April 15, the 21st Conference…
Committed to Empowering Customers’ Transition to Net Zero, INNIO Opens Two Training Centers in China
GUANGDONG, CHINA, Apr 18, 2023 – (ACN Newswire) – INNIO Group today announced that it…
Three Weeks Until ISDA’s 37th AGM in Chicago – Did You Register?
–(BUSINESS WIRE)–#BenchmarkReform–Join the International Swaps and Derivatives Association, Inc. (ISDA) at its 37th Annual General…
Technology as a Driver in CX Transformation and Business Growth
By Brett Sharp, Sr. Director of Customer Experience, Synoptek Customer Experience (CX) strategy is critical…
SumUp Announces New Global ESG Initiatives To Support Sustainability Efforts
12 April 2023, London: Global financial technology company SumUp (https://www.sumup.com/en-gb/) continues its industry-leading sustainability agenda,…
Cycode Launches Application Security Orchestration and Correlation Solution to Streamline Vulnerability Testing and Remediation
Cycode ASOC Dashboard Cycode Launches Application Security Orchestration and Correlation (ASOC) Solution to Streamline Vulnerability…
Cycode Launches Application Security Orchestration and Correlation Solution to Streamline Vulnerability Testing and Remediation
Cycode ASOC Dashboard Cycode Launches Application Security Orchestration and Correlation (ASOC) Solution to Streamline Vulnerability…
Second Edition of Best-Selling Book, How to Measure Anything in Cyber Risk, Launches Globally
Author Richard Seiersen provides a start-to-finish guide for realistically measuring cybersecurity risk, a core step…
SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy
– Investment will advance Epic’s lead program, EPI-321, toward clinic in 2024 – SOUTH SAN…
SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy
– Investment will advance Epic’s lead program, EPI-321, toward clinic in 2024 – SOUTH SAN…
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1…
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1…
Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic…
Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…